RxDoctor Payments Data

Mauro Ganzon, MD

Family Medicine · Boyd, TXNPI 1932165503

Payments from drug & device makers

$6,225in general payments, 2019–2025

Across 351 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Romark Laboratories, LC$669
  • AbbVie$651
  • Boehringer Ingelheim$642
  • Merck$390
  • Novo Nordisk$384
  • Antares Pharma, Inc.$324
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,219100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,225 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,807
Medicare patients
183
Services billed
2,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$56,336
MounjaroTirzepatide38$50,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$25,917
JardianceEmpagliflozin17$17,808
XareltoRivaroxaban15$16,473
EliquisApixaban11$13,343
JanuviaSitagliptin Phosphate13$10,902
MyrbetriqMirabegron12$10,702
VascepaIcosapent Ethyl11$10,635
Spiriva RespimatTiotropium Bromide14$7,896
PremarinEstrogens, Conjugated11$7,693
SymbicortBudesonide/Formoterol Fumarate12$4,029
Omega-3 Acid Ethyl Esters24$2,902
Pregabalin24$2,496
Ezetimibe40$1,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$384$56,33643 claims
Lilly USA, LLCMounjaro$233$50,87638 claims
GSKTrelegy Ellipta$85$25,91724 claims
Boehringer IngelheimJardiance, Spiriva Respimat$642$25,70331 claims
PfizerEliquis, Premarin$164$21,03722 claims
Johnson & JohnsonXarelto$202$16,47315 claims
MerckJanuvia$390$10,90213 claims
Astellas Pharma US IncMyrbetriq$210$10,70212 claims
AstraZenecaSymbicort$253$4,02912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Boyd

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →